Search for other papers by Peter D Mark in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Claus L Petersen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Andreas Kjaer in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
been calculated that, to detect a clinical relevant change in LVM in a randomized, placebo-controlled study, less than one-twentieth the number of subjects is necessary using cardiac MRI when compared with echocardiography (16) . The main findings of
Search for other papers by Aglaia Kyrilli in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Department of Gynecology and Obstetrics, Copenhagen University Hospital (Hvidovre Hospital), Hvidovre, Denmark
Search for other papers by Sofie Bliddal in
Google Scholar
PubMed
Carelink Nærhospital, Roskilde, Denmark
Search for other papers by Dorthe Hansen Precht in
Google Scholar
PubMed
Institute of Clinical Medicine, Faculty of Health and Clinical Research, Copenhagen University, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Université Libre de Bruxelles (ULB), Brussels, Belgium
Search for other papers by Kris Poppe in
Google Scholar
PubMed
that LT4 initiated preconceptionally and continued throughout pregnancy did not decrease the risk of pregnancy loss or preterm delivery as compared to placebo, neither in spontaneous nor in vitro fertilization (IVF) obtained pregnancies ( 14 , 15
Search for other papers by Giuseppe Lisco in
Google Scholar
PubMed
Search for other papers by Anna De Tullio in
Google Scholar
PubMed
Search for other papers by Olga Disoteo in
Google Scholar
PubMed
Search for other papers by Giuseppina Piazzolla in
Google Scholar
PubMed
Search for other papers by Edoardo Guastamacchia in
Google Scholar
PubMed
Search for other papers by Carlo Sabbà in
Google Scholar
PubMed
Search for other papers by Vincenzo De Geronimo in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Vincenzo Triggiani in
Google Scholar
PubMed
placebo is an additional source of bias, as it is unclear if other drugs over GLP-1RAs may have protective, neutral, or detrimental effects on thyroid carcinogenesis. Third, the incidence of thyroid cancer ranks ninth worldwide. Although it is more
Department of Performance and Image-enhancing Drugs Research, Android Health Clinic, Utrecht, the Netherlands
Search for other papers by Peter Bond in
Google Scholar
PubMed
Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands
Search for other papers by Tijs Verdegaal in
Google Scholar
PubMed
Department of Performance and Image-enhancing Drugs Research, Android Health Clinic, Utrecht, the Netherlands
Search for other papers by Diederik L Smit in
Google Scholar
PubMed
its stimulating effect on erythropoiesis can be beneficial for the correction of anemia in some patients, the same effect can lead to erythrocytosis in others – with a nearly fourfold greater risk for erythrocytosis compared with placebo ( 5
Search for other papers by Changwei Liu in
Google Scholar
PubMed
Search for other papers by Jingwen Wang in
Google Scholar
PubMed
Search for other papers by Yuanyuan Wan in
Google Scholar
PubMed
Search for other papers by Xiaona Xia in
Google Scholar
PubMed
Search for other papers by Jian Pan in
Google Scholar
PubMed
Search for other papers by Wei Gu in
Google Scholar
PubMed
Search for other papers by Mei Li in
Google Scholar
PubMed
. In our study, HbA1c was associated with 25OHD levels in established T1DM. In a randomized, double-blind, placebo-controlled trial, 30 young patients with new-onset T1DM assigned to cholecalciferol or placebo for 12 months, showed that
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Michael Ulm in
Google Scholar
PubMed
Search for other papers by Arvind V Ramesh in
Google Scholar
PubMed
Search for other papers by Keely M McNamara in
Google Scholar
PubMed
Search for other papers by Suriyan Ponnusamy in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Ramesh Narayanan in
Google Scholar
PubMed
the AA group compared to 10.9 months in the placebo group, and median time for PSA progression increased from 6.6 months to 10.2 months ( 21 ). Unfortunately, patients treated with abiraterone experience a relapse of CRPC within 2 years after treatment
1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Kosmas Daskalakis in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Evanthia Kassi in
Google Scholar
PubMed
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Search for other papers by Denise Kolomodi in
Google Scholar
PubMed
Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, UK
Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
the other hand, angiogenesis in NENs is of paramount importance, though not yet fully explained ( 11 ). A large placebo-controlled phase III trial has demonstrated that sunitinib, which is a potent multi-targeted RTK inhibitor of VEGFR1-3, PDGFR
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
, placebo control study documented the reversal of atherogenic lipid profile, which go hand-in-hand with improvement in body composition following r-hGH in acromegaly patients who were GHD (9) . The data on the effect of GH replacement in patients of
European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany
Search for other papers by Daniel Alexander Hescheler in
Google Scholar
PubMed
Search for other papers by Milan Janis Michael Hartmann in
Google Scholar
PubMed
Search for other papers by Burkhard Riemann in
Google Scholar
PubMed
Search for other papers by Maximilian Michel in
Google Scholar
PubMed
Search for other papers by Christiane Josephine Bruns in
Google Scholar
PubMed
Search for other papers by Hakan Alakus in
Google Scholar
PubMed
Search for other papers by Costanza Chiapponi in
Google Scholar
PubMed
, randomized, two arms, double blind, placebo controlled, active – not recruiting OS Placebo: 29.0% OS Pazopanib: 37.1% (clinicaltrials.gov) N/A Pembrolizumab, Trametinib and Dabrafenib NCT04675710 Pembrolizumab: PD-1 receptor Dabrafenib: BRAF V
Search for other papers by Madalena von Hafe in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by João Sergio Neves in
Google Scholar
PubMed
Search for other papers by Catarina Vale in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by Marta Borges-Canha in
Google Scholar
PubMed
Search for other papers by Adelino Leite-Moreira in
Google Scholar
PubMed
/day) compared with the placebo group ( 59 ). While some studies show a decrease in triglyceride levels, other studies detected lower levels of apolipoprotein B-100 in the treated group ( 106 ). The role of THs in preventing cardiac ischemia has not been